Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2

Science Translational Medicine

Volumn 10, Issue 432, 2018, Pages

  Incio, Joao ^a,b,c   Ligibel, Jennifer A ^d   McManus, Daniel T ^a,i   Suboj, Priya ^a,e   Jung, Keehoon ^a   Kawaguchi, Kosuke ^a   Pinter, Matthias ^a,f   Babykutty, Suboj ^a,g   Chin, Shan M ^h   Vardam, Trupti D ^a,j   Huang, Yuhui ^a,k   Rahbari, Nuh N ^a,l   Roberge, Sylvie ^a   Wang, Dannie ^a,m   Gomes Santos, Igor L ^a   Puchner, Stefan B ^a,f   Schlett, Christopher L ^a,n   Hoffmman, Udo ^a   Ancukiewicz, Marek ^a,o   Tolaney, Sara M ^d   Krop, Ian E ^d   Duda, Dan G ^a   Boucher, Yves ^a   Fukumura, Dai ^a   Jain, Rakesh K ^a   more..

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF PORTO   (Portugal)

^c HOSPITAL DE SÃO JOÃO   (Portugal)

^d HARVARD MEDICAL SCHOOL   (United States)

^e St Xaviers College Thiruvananthapuram   (India)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g MAR IVANIOS COLLEGE   (India)

^h UNIVERSITY OF SÃO PAULO   (Brazil)

ⁱ NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^j MAYO CLINIC   (United States)

^k SOOCHOW UNIVERSITY   (China)

^l MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^m Radius Health Inc   (United States)

ⁿ UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^o ALNYLAM PHARMACEUTICALS   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; AZD 4547; BEVACIZUMAB; CARBONATE DEHYDRATASE IX; DOXORUBICIN; FIBROBLAST GROWTH FACTOR 2; GLUCOSE TRANSPORTER 1; INTERLEUKIN 6; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY B20; PROTEIN KINASE B; S6 KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; ANTINEOPLASTIC AGENT; VASCULOTROPIN A;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BODY MASS; BONE MARROW CELL; BREAST CANCER; CANCER PROGNOSIS; CANCER RESISTANCE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIET INDUCED OBESITY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HUMAN; HUMAN TISSUE; INTRA-ABDOMINAL FAT; MAJOR CLINICAL STUDY; METASTASIS; MOUSE; NONHUMAN; OBESITY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SUBCUTANEOUS FAT; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; TUMOR HYPOXIA; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; UPREGULATION; ANIMAL; BREAST TUMOR; COMPLICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; INTERLEUKIN-6; METFORMIN; MICE; OBESITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85043769890     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aag0945     Document Type: Article

References (92)

1. R. K. Jain, Normalizing tumor microenvironment to treat cancer: Bench to bedside to biomarkers. J. Clin. Oncol. 31, 2205-2218 (2013).
2. R. K. Jain, Antiangiogenesis strategies revisited: From starving tumors to alleviating hypoxia. Cancer Cell 26, 605-622 (2014).
3. A. E. Lohmann, S. Chia, Patients with metastatic breast cancer using bevacizumab as a treatment: Is there still a role for it? Curr. Treat. Options Oncol. 13, 249-262 (2012).
4. B. Guiu, J. M. Petit, F. Bonnetain, S. Ladoire, S. Guiu, J.-P. Cercueil, D. Krausé, P. Hillon, C. Borg, B. Chauffert, F. Ghiringhelli, Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer. Gut 59, 341-347 (2010).
5. S. Ladoire, F. Bonnetain, M. Gauthier, S. Zanetta, J. M. Petit, S. Guiu, I. Kermarrec, E. Mourey, F. Michel, D. Krause, P. Hillon, L. Cormier, F. Ghiringhelli, B. Guiu, Visceral fat area as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with antiangiogenic agents. Oncologist 16, 71-81 (2011).
6. A. Gati, S. Kouidhi, R. Marrakchi, A. El Gaaied, N. Kourda, A. Derouiche, M. Chebil, A. Caignard, A. Perier, Obesity and renal cancer: Role of adipokines in the tumor-immune system conflict. Oncoimmunology 3, e27810 (2014).
7. S. Steffens, V. Grünwald, K. I. Ringe, C. Seidel, H. Eggers, M. Schrader, F. Wacker, M. A. Kuczyk, A. J. Schrader, Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor-Targeted therapy? Oncologist 16, 1565-1571 (2011).
8. R. K. Jain, D. G. Duda, C. G. Willett, D. V. Sahani, A. X. Zhu, J. S. Loeffler, T. T. Batchelor, A. G. Sorensen, Biomarkers of response and resistance to antiangiogenic therapy. Nat. Rev. Clin. Oncol. 6, 327-338 (2009).
9. P. Carmeliet, R. K. Jain, Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298-307 (2011).
10. D. G. Duda, L. L. Munn, R. K. Jain, Can we identify predictive biomarkers for antiangiogenic therapy of cancer using mathematical modeling? J. Natl. Cancer Inst. 105, 762-765 (2013).
11. P. Carmeliet, R. K. Jain, Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat. Rev. Drug Discov. 10, 417-427 (2011).
12. J. Ye, Z. Gao, J. Yin, Q. He, Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am. J. Physiol. Endocrinol. Metab. 293, E1118-E1128 (2007).
13. J. Incio, R. Soares, Obesity, diabetes and metabolic syndrome impact on tumor angiogenesis, in Tumor Angiogenesis Regulators, R. R. Gonzalez-Perez, B. R. Rueda, Eds. (CRC Press, 2013).
14. S. Khan, S. Shukla, S. Sinha, S. M. Meeran, Role of adipokines and cytokines in obesity-Associated breast cancer: Therapeutic targets. Cytokine Growth Factor Rev. 24, 503-513 (2013).
15. D. Fukumura, J. Incio, R. C. Shankaraiah, R. K. Jain, Obesity and Cancer: An angiogenic and inflammatory link. Microcirculation 23, 191-206 (2016).
16. C. Costa, J. Incio, R. Soares, Angiogenesis and chronic inflammation: Cause or consequence? Angiogenesis 10, 149-166 (2007).
17. N. Hosogai, A. Fukuhara, K. Oshima, Y. Miyata, S. Tanaka, K. Segawa, S. Furukawa, Y. Tochino, R. Komuro, M. Matsuda, I. Shimomura, Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 56, 901-911 (2007).
18. S. D. Hursting, Minireview: The year in obesity and cancer. Mol. Endocrinol. 26, 1961-1966 (2012).
19. H. R. Lijnen, Angiogenesis and obesity. Cardiovasc. Res. 78, 286-293 (2008).
20. Y. Y. Wang, C. Lehuédé, V. Laurent, B. Dirat, S. Dauvillier, L. Bochet, S. Le Gonidec, G. Escourrou, P. Valet, C. Muller, Adipose tissue and breast epithelial cells: A dangerous dynamic duo in breast cancer. Cancer Lett. 324, 142-151 (2012).
21. J. Incio, H. Liu, P. Suboj, S. M. Chin, I. X. Chen, M. Pinter, M. R. Ng, H. T. Nia, J. Grahovac, S. Kao, S. Babykutty, Y. Huang, K. Jung, N. N. Rahbari, X. Han, V. P. Chauhan, J. D. Martin, J. Kahn, P. Huang, V. Desphande, J. Michaelson, T. P. Michelakos, C. R. Ferrone, R. Soares, Y. Boucher, D. Fukumura, R. K. Jain, Obesity-induced inflammation and desmoplasia promote pancreatic cancer progression and resistance to chemotherapy. Cancer Discov. 6, 852-869 (2016).
22. J. Incio, J. Tam, N. N. Rahbari, P. Suboj, D. T. McManus, S. M. Chin, T. D. Vardam, A. Batista, S. Babykutty, K. Jung, A. Khachatryan, T. Hato, J. A. Ligibel, I. E. Krop, S. B. Puchner, C. L. Schlett, U. Hoffmman, M. Ancukiewicz, M. Shibuya, P. Carmeliet, R. Soares, D. G. Duda, R. K. Jain, D. Fukumura, PlGF/VEGFR-1 signaling promotes macrophage polarization and accelerated tumor progression in obesity. Clin. Cancer Res. 22, 2993-3004 (2016).
23. J. A. Sparano, M. Wang, F. Zhao, V. Stearns, S. Martino, J. A. Ligibel, E. A. Perez, T. Saphner, A. C. Wolff, G. W. Sledge Jr., W. C. Wood, J. Fetting, N. E. Davidson, Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer 118, 5937-5946 (2012).
24. S. M. Tolaney, Y. Boucher, D. G. Duda, J. D. Martin, G. Seano, M. Ancukiewicz, W. T. Barry, S. Goel, J. Lahdenrata, S. J. Isakoff, E. D. Yeh, S. R. Jain, M. Golshan, J. Brock, M. Snuderl, E. P. Winer, I. E. Krop, R. K. Jain, Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. Proc. Natl. Acad. Sci. U.S.A. 112, 14325-14330 (2015).
25. P. Trayhurn, Hypoxia and adipose tissue function and dysfunction in obesity. Physiol. Rev. 93, 1-21 (2013).
26. S. Mottagui-Tabar, M. Rydén, P. Löfgren, G. Faulds, J. Hoffstedt, A. J. Brookes, I. Andersson, P. Arner, Evidence for an important role of perilipin in the regulation of human adipocyte lipolysis. Diabetologia 46, 789-797 (2003).
27. B. Dirat, L. Bochet, M. Dabek, D. Daviaud, S. Dauvillier, B. Majed, Y. Y. Wang, A. Meulle, B. Salles, S. Le Gonidec, I. Garrido, G. Escourrou, P. Valet, C. Muller, Cancer-Associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Res. 71, 2455-2465 (2011).
28. D. Fukumura, R. K. Jain, Tumor microvasculature and microenvironment: Targets for anti-Angiogenesis and normalization. Microvasc. Res. 74, 72-84 (2007).
29. D. G. Duda, M. Ancukiewicz, R. K. Jain, Biomarkers of antiangiogenic therapy: How do we move from candidate biomarkers to valid biomarkers? J. Clin. Oncol. 28, 183-185 (2010).
30. Y. Rattigan, J. M. Hsu, P. J. Mishra, J. Glod, D. Banerjee, Interleukin 6 mediated recruitment of mesenchymal stem cells to the hypoxic tumor milieu. Exp. Cell Res. 316, 3417-3424 (2010).
31. J. Hong, N. P. Tobin, H. Rundqvist, T. Li, M. Lavergne, Y. García-Ibáñez, H. Qin, J. Paulsson, M. Zeitelhofer, M. Z. Adzemovic, I. Nilsson, P. Roswall, J. Hartman, R. S. Johnson, A. Ostman, J. Bergh, M. Poljakovic, G. Genové, Role of tumor pericytes in the recruitment of myeloid-derived suppressor cells. J. Natl. Cancer Inst. 107, 209 (2015).
32. Z. Li, Y. Pang, S. K. Gara, B. R. Achyut, C. Heger, P. K. Goldsmith, S. Lonning, L. Yang, Gr-1+CD11b+ cells are responsible for tumor promoting effect of TGF-β in breast cancer progression. Int. J. Cancer 131, 2584-2595 (2012).
33. S. Spranger, R. M. Spaapen, Y. Zha, J. Williams, Y. Meng, T. T. Ha, T. F. Gajewski, Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci. Transl. Med. 5, 200ra116 (2013).
34. H. M. Kluger, D. Chelouche Lev, Y. Kluger, M. M. McCarthy, G. Kiriakova, R. L. Camp, D. L. Rimm, J. E. Price, Using a xenograft model of human breast cancer metastasis to find genes associated with clinically aggressive disease. Cancer Res. 65, 5578-5587 (2005).
35. V. P. Chauhan, J. D. Martin, H. Liu, D. A. Lacorre, S. R. Jain, S. V. Kozin, T. Stylianopoulos, A. S. Mousa, X. Han, P. Adstamongkonkul, Z. Popović, P. Huang, M. G. Bawendi, Y. Boucher, R. K. Jain, Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumor blood vessels. Nat. Commun. 4, 2516 (2013).
36. O. Casanovas, D. J. Hicklin, G. Bergers, D. Hanahan, Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8, 299-309 (2005).
37. C. Lieu, J. Heymach, M. Overman, H. Tran, S. Kopetz, Beyond VEGF: Inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin. Cancer Res. 17, 6130-6139 (2011).
38. R. Gyanchandani, M. V. Ortega Alves, J. N. Myers, S. Kim, A proangiogenic signature is revealed in FGF-mediated bevacizumab-resistant head and neck squamous cell carcinoma. Mol. Cancer Res. 11, 1585-1596 (2013).
39. X. F. Wang, J. Y. Zhang, L. Li, X. Y. Zhao, Beneficial effects of metformin on primary cardiomyocytes via activation of adenosine monophosphate-Activated protein kinase. Chin. Med. J. 124, 1876-1884 (2011).
40. P. Muti, F. Berrino, V. Krogh, A. Villarini, M. Barba, S. Strano, G. Blandino, Metformin, diet and breast cancer: An avenue for chemoprevention. Cell Cycle 8, 2661 (2009).
41. J. Incio, P. Suboj, S. M. Chin, T. Vardam-Kaur, H. Liu, T. Hato, S. Babykutty, I. Chen, V. Deshpande, R. K. Jain, D. Fukumura, Metformin reduces desmoplasia in pancreatic cancer by reprogramming stellate cells and tumor-Associated macrophages. PLOS ONE 10, e0141392 (2015).
42. L. Bochet, A. Meulle, S. Imbert, B. Salles, P. Valet, C. Muller, Cancer-Associated adipocytes promotes breast tumor radioresistance. Biochem. Biophys. Res. Commun. 411, 102-106 (2011).
43. N. Halberg, T. Khan, M. E. Trujillo, I. Wernstedt-Asterholm, A. D. Attie, S. Sherwani, Z. V. Wang, S. Landskroner-Eiger, S. Dineen, U. J. Magalang, R. A. Brekken, P. E. Scherer, Hypoxia-inducible factor 1αinduces fibrosis and insulin resistance in white adipose tissue. Mol. Cell. Biol. 29, 4467-4483 (2009).
44. N. J. Zyromski, A. Mathur, H. A. Pitt, T. E. Wade, S. Wang, P. Nakshatri, D. A. Swartz-Basile, H. Nakshatri, Obesity potentiates the growth and dissemination of pancreatic cancer. Surgery 146, 258-263 (2009).
45. P. B. White, E. M. True, K. M. Ziegler, S. S. Wang, D. A. Swartz-Basile, H. A. Pitt, N. J. Zyromski, Insulin, leptin, and tumoral adipocytes promote murine pancreatic cancer growth. J. Gastrointest. Surg. 14, 1888-1893; discussion 1893-1894 (2010).
46. Y. Zhang, A. C. Daquinag, F. Amaya-Manzanares, O. Sirin, C. Tseng, M. G. Kolonin, Stromal progenitor cells from endogenous adipose tissue contribute to pericytes and adipocytes that populate the tumor microenvironment. Cancer Res. 72, 5198-5208 (2012).
47. E. E. Calle, R. Kaaks, Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms. Nat. Rev. Cancer 4, 579-591 (2004).
48. E. Fuentes-Mattei, G. Velazquez-Torres, L. Phan, F. Zhang, P.-C. Chou, J.-H. Shin, H. H. Choi, J.-S. Chen, R. Zhao, J. Chen, C. Gully, C. Carlock, Y. Qi, Y. Zhang, Y. Wu, F. J. Esteva, Y. Luo, W. L. McKeehan, J. Ensor, G. N. Hortobagyi, L. Pusztai, W. Fraser Symmans, M.-H. Lee, S.-C. Yeung, Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer. J. Natl. Cancer Inst. 106, 158 (2014).
49. S. Sathornsumetee, Y. Cao, J. E. Marcello, J. E. Herndon II, R. E. McLendon, A. Desjardins, H. S. Friedman, M. W. Dewhirst, J. J. Vredenburgh, J. N. Rich, Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J. Clin. Oncol. 26, 271-278 (2008).
50. G. Bergers, D. Hanahan, Modes of resistance to anti-Angiogenic therapy. Nat. Rev. Cancer 8, 592-603 (2008).
51. Y. S. Hong, H. J. Cho, S. Y. Kim, K. H. Jung, J. W. Park, H. S. Choi, J. H. Oh, B. C. Kim, D. K. Sohn, D. Y. Kim, H. J. Chang, Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer. BMC Cancer 9, 246 (2009).
52. B. Bao, S. Ali, A. Ahmad, A. S. Azmi, Y. Li, S. Banerjee, D. Kong, S. Sethi, A. Aboukameel, S. B. Padhye, F. H. Sarkar, Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment. PLOS ONE 7, e50165 (2012).
53. A. K. Sasser, N. J. Sullivan, A. W. Studebaker, L. F. Hendey, A. E. Axel, B. M. Hall, Interleukin-6 is a potent growth factor for ER-α-positive human breast cancer. FASEB J. 21, 3763-3770 (2007).
54. P. Sansone, G. Storci, S. Tavolari, T. Guarnieri, C. Giovannini, M. Taffurelli, C. Ceccarelli, D. Santini, P. Paterini, K. B. Marcu, P. Chieco, M. Bonafè, IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J. Clin. Invest. 117, 3988-4002 (2007).
55. N. J. Sullivan, A. K. Sasser, A. E. Axel, F. Vesuna, V. Raman, N. Ramirez, T. M. Oberyszyn, B. M. Hall, Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene 28, 2940-2947 (2009).
56. P. Trayhurn, B. Wang, I. S. Wood, Hypoxia and the endocrine and signalling role of white adipose tissue. Arch. Physiol. Biochem. 114, 267-276 (2008).
57. J. Ye, Emerging role of adipose tissue hypoxia in obesity and insulin resistance. Int. J. Obes. 33, 54-66 (2009).
58. P. Trayhurn, B. Wang, I. S. Wood, HIF-1α protein rather than mRNA as a marker of hypoxia in adipose tissue in obesity: Focus on "Inflammation is associated with a decrease of lipogenic factors in omental fat in women, " by Poulain-Godefroy et al. Am. J. Physiol. Regul. Integr. Comp. Physiol. 295, R1097; author reply R1098 (2008).
59. D. Fukumura, D. G. Duda, L. L. Munn, R. K. Jain, Tumor microvasculature and microenvironment: Novel insights through intravital imaging in pre-clinical models. Microcirculation 17, 206-225 (2010).
60. J. H. Kim, R. A. Bachmann, J. Chen, Interleukin-6 and insulin resistance. Vitam. Horm. 80, 613-633 (2009).
61. H. S. Park, J. Y. Park, R. Yu, Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-α and IL-6. Diabetes Res. Clin. Pract. 69, 29-35 (2005).
62. L. W. Bowers, D. A. Cavazos, I. X. F. Maximo, A. J. Brenner, S. D. Hursting, L. A. deGraffenried, Obesity enhances nongenomic estrogen receptor crosstalk with the PI3K/Akt and MAPK pathways to promote in vitro measures of breast cancer progression. Breast Cancer Res. 15, R59 (2013).
63. R. Kolb, L. Phan, N. Borcherding, Y. Liu, F. Yuan, A. M. Janowski, Q. Xie, K. R. Markan, W. Li, M. J. Potthoff, E. Fuentes-Mattei, L. G. Ellies, C. M. Knudson, M.-H. Lee, S.-J. Yeung, S. L. Cassel, F. S. Sutterwala, W. Zhang, Obesity-Associated NLRC4 inflammasome activation drives breast cancer progression. Nat. Commun. 7, 13007 (2016).
64. Q. Chang, E. Bournazou, P. Sansone, M. Berishaj, S. P. Gao, L. Daly, J. Wels, T. Theilen, S. Granitto, X. Zhang, J. Cotari, M. L. Alpaugh, E. de Stanchina, K. Manova, M. Li, M. Bonafe, C. Ceccarelli, M. Taffurelli, D. Santini, G. Altan-Bonnet, R. Kaplan, L. Norton, N. Nishimoto, D. Huszar, D. Lyden, J. Bromberg, The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. Neoplasia 15, 848-862 (2013).
65. H. Knüpfer, R. Preiss, Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res. Treat. 102, 129-135 (2007).
66. A. Sanguinetti, D. Santini, M. Bonafe, M. Taffurelli, N. Avenia, Interleukin-6 and pro inflammatory status in the breast tumor microenvironment. World J. Surg. Oncol. 13, 129 (2015).
67. A. Saidi, M. Hagedorn, N. Allain, C. Verpelli, C. Sala, L. Bello, A. Bikfalvi, S. Javerzat, Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness. Int. J. Cancer 125, 1054-1064 (2009).
68. D. G. Remick, Interleukin-8. Crit. Care Med. 33, S466-S467 (2005).
69. D. G. Remick, G. Bolgos, S. Copeland, J. Siddiqui, Role of interleukin-6 in mortality from and physiologic response to sepsis. Infect. Immun. 73, 2751-2757 (2005).
70. J. Chen, Y. Ye, P. Liu, W. Yu, F. Wei, H. Li, J. Yu, Suppression of T cells by myeloid-derived suppressor cells in cancer. Human Immunol. 78, 113-119 (2016).
71. M. Pedroza, D. J. Schneider, H. Karmouty-Quintana, J. Coote, S. Shaw, R. Corrigan, J. G. Molina, J. L. Alcorn, D. Galas, R. Gelinas, M. R. Blackburn, Interleukin-6 contributes to inflammation and remodeling in a model of adenosine mediated lung injury. PLOS ONE 6, e22667 (2011).
72. R. Giavazzi, B. Sennino, D. Coltrini, A. Garofalo, R. Dossi, R. Ronca, M. P. Tosatti, M. Presta, Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis. Am. J. Pathol. 162, 1913-1926 (2003).
73. J. M. Clarke, H. I. Hurwitz, Understanding and targeting resistance to anti-Angiogenic therapies. J. Gastrointest. Oncol. 4, 253-263 (2013).
74. W. W. Wheaton, S. E. Weinberg, R. B. Hamanaka, S. Soberanes, L. B. Sullivan, E. Anso, A. Glasauer, E. Dufour, G. M. Mutlu, G. S. Budigner, N. S. Chandel, Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. eLife 3, e02242 (2014).
75. S. Indraccolo, G. Randon, E. Zulato, M. Nardin, C. Aliberti, F. Pomerri, A. Casarin, M. O. Nicoletto, Metformin: A modulator of bevacizumab activity in cancer? A case report. Cancer Biol. Ther. 16, 210-214 (2015).
76. A. R. Carmichael, Obesity and prognosis of breast cancer. Obes. Rev. 7, 333-340 (2006).
77. C. La Vecchia, E. Negri, S. Franceschi, R. Talamini, P. Bruzzi, D. Palli, A. Decarli, Body mass index and post-menopausal breast cancer: An age-specific analysis. Br. J. Cancer 75, 441-444 (1997).
78. A. G. Renehan, M. Tyson, M. Egger, R. F. Heller, M. Zwahlen, Body-mass index and incidence of cancer: A systematic review and meta-Analysis of prospective observational studies. Lancet 371, 569-578 (2008).
79. M. Protani, M. Coory, J. H. Martin, Effect of obesity on survival of women with breast cancer: Systematic review and meta-Analysis. Breast Cancer Res. Treat. 123, 627-635 (2010).
80. T. Scully, S. M. Firth, C. D. Scott, H. C. de Silva, J. E. Pintar, T. Chan-Ling, S. M. Twigg, R. C. Baxter, Insulin-like growth factor binding protein-3 links obesity and breast cancer progression. Oncotarget 7, 55491-55505 (2016).
81. C. T. Chen, Y. Du, H. Yamaguchi, J. M. Hsu, H. P . Kuo, G. N. Hortobagyi, M. C. Hung, Targeting the IKKβ/mTOR/VEGF signaling pathway as a potential therapeutic strategy for obesity-related breast cancer. Mol. Cancer Ther. 11, 2212-2221 (2012).
82. G. W. Kim, N. R. Lee, R. H. Pi, Y. S. Lim, Y. M. Lee, J. M. Lee, H. S. Jeong, S. H. Chung, IL-6 inhibitors for treatment of rheumatoid arthritis: Past, present, and future. Arch. Pharm. Res. 38, 575-584 (2015).
83. J. A. Ligibel, C. M. Alfano, D. Hershman, R. M. Ballard, S. S. Bruinooge, K. S. Courneya, E. C. Daniels, W. Demark-Wahnefried, E. S. Frank, P. J. Goodwin, M. L. Irwin, L. A. Levit, W. McCaskill-Stevens, L. M. Minasian, M. A. O'Rourke, J. P. Pierce, K. D. Stein, C. A. Thomson, C. A. Hudis, Recommendations for obesity clinical trials in cancer survivors: American Society of Clinical Oncology statement. J. Clin. Oncol. 33, 3961-3967 (2015).
84. T. Irlbeck, J. M. Massaro, F. Bamberg, C. J. O'Donnell, U. Hoffmann, C. S. Fox, Association between single-slice measurements of visceral and abdominal subcutaneous adipose tissue with volumetric measurements: The Framingham Heart Study. Int. J. Obes. 34, 781-787 (2010).
85. G. A. Borkan, S. G. Gerzof, A. H. Robbins, D. E. Hults, C. K. Silbert, J. E. Silbert, Assessment of abdominal fat content by computed tomography. Am. J. Clin. Nutr. 36, 172-177 (1982).
86. P. Maurovich-Horvat, J. Massaro, C. S. Fox, F. Moselewski, C. J. O'Donnell, U. Hoffmann, Comparison of anthropometric, area-And volume-based assessment of abdominal subcutaneous and visceral adipose tissue volumes using multi-detector computed tomography. Int. J. Obes. 31, 500-506 (2007).
87. J. Tam, D. G. Duda, J. Y. Perentes, R. S. Quadri, D. Fukumura, R. K. Jain, Blockade of VEGFR2 and not VEGFR1 can limit diet-induced fat tissue expansion: Role of local versus bone marrow-derived endothelial cells. PLOS ONE 4, e4974 (2009).
88. Y. Wu, P. Brodt, H. Sun, W. Mejia, R. Novosyadlyy, N. Nunez, X. Chen, A. Mendoza, S.-H. Hong, C. Khanna, S. Yakar, Insulin-like growth factor-I regulates the liver microenvironment in obese mice and promotes liver metastasis. Cancer Res. 70, 57-67 (2010).
89. T. Kanda, A. Raychoudhuri, R. Steele, J. E. Sagartz, C. West, R. B. Ray, MBP-1 inhibits breast cancer growth and metastasis in immunocompetent mice. Cancer Res. 69, 9354-9359 (2009).
90. V. Silobrcic, H. D. Suit, Tumor-specific antigen(s) in a spontaneous mammary carcinoma of C3H mice. I. Quantitative cell transplants into mammary-Tumor-Agent-positive and -free mice. J. Natl. Cancer Inst. 39, 1113-1119 (1967).
91. S. Reagan-Shaw, M. Nihal, N. Ahmad, Dose translation from animal to human studies revisited. FASEB J. 22, 659-661 (2008).
92. Aperio, Positive Pixel Count Algorithm (Aperio, 2009); http://tmalab.jhmi.edu/aperiou/userguides/Positive-Pixel.pdf.